TRIMTECH has a growing pipeline of potent, CNS (central nervous system) penetrant therapeutics based on its aggregate-selective degrader molecules known as TRIMTACs and TRIMGLUEs. The pipeline is focused around the development of treatments for severe neurodegenerative and inflammatory disorders, including Alzheimer’s and Huntington’s disease.
| Website | https://trimtechtherapeutics.com |
| Employees | 20 (10 on RocketReach) |
| Founded | 2023 |
| Industry | Biotechnology Research |
Looking for a particular TRIMTECH Therapeutics Limited employee's phone or email?
Nicki Thompson is the CEO of TRIMTECH Therapeutics Limited.
10 people are employed at TRIMTECH Therapeutics Limited.